Can we boost genetic testing for advanced prostate cancer?
NCT ID NCT07209176
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to increase the use of next-generation sequencing (NGS) testing in men with metastatic prostate cancer at Johns Hopkins. Researchers will test ways to overcome barriers for both doctors and patients. About 256 men newly diagnosed with metastatic prostate cancer will take part. The goal is to see if these efforts lead to more patients getting tested.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
RECRUITINGBaltimore, Maryland, 21205, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Can a blood filtering technique reveal more about prostate cancer spread?
- Can a vaccine plus immune booster tackle resistant prostate cancer?
- Can a smart drug deliver a toxic payload to prostate cancer cells?
- Can a blast of testosterone shrink hard-to-treat prostate cancer?
- A PET scan and a blood test may predict which men with advanced prostate cancer will benefit from targeted therapy